Phenome-wide association studies across large population cohorts support drug target validation.

Nat Commun
Authors
Keywords
Abstract

Phenome-wide association studies (PheWAS) have been proposed as a possible aid in drug development through elucidating mechanisms of action, identifying alternative indications, or predicting adverse drug events (ADEs). Here, we select 25 single nucleotide polymorphisms (SNPs) linked through genome-wide association studies (GWAS) to 19 candidate drug targets for common disease indications. We interrogate these SNPs by PheWAS in four large cohorts with extensive health information (23andMe, UK Biobank, FINRISK, CHOP) for association with 1683 binary endpoints in up to 697,815 individuals and conduct meta-analyses for 145 mapped disease endpoints. Our analyses replicate 75% of known GWAS associations (P 

Year of Publication
2018
Journal
Nat Commun
Volume
9
Issue
1
Pages
4285
Date Published
2018 10 16
ISSN
2041-1723
DOI
10.1038/s41467-018-06540-3
PubMed ID
30327483
PubMed Central ID
PMC6191429
Links